Abstract
Gastric cancer imposes a considerable health burden worldwide, and its mortality ranks as the second highest for all types of cancers. The limited knowledge of the molecular mechanisms underlying gastric cancer tumorigenesis hinders the development of therapeutic strategies. However, ongoing collaborative sequencing efforts facilitate molecular classification and unveil the genomic landscape of gastric cancer. Several new drivers and tumorigenic pathways in gastric cancer, including chromatin remodeling genes, RhoA-related pathways, TP53 dysregulation, activation of receptor tyrosine kinases, stem cell pathways and abnormal DNA methylation, have been revealed. These newly identified genomic alterations await translation into clinical diagnosis and targeted therapies. Considering that loss-of-function mutations are intractable, synthetic lethality could be employed when discussing feasible therapeutic strategies. Although many challenges remain to be tackled, we are optimistic regarding improvements in the prognosis and treatment of gastric cancer in the near future.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Abe, H., Maeda, D., Hino, R., Otake, Y., Isogai, M., Ushiku, A.S., Matsusaka, K., Kunita, A., Ushiku, T., Uozaki, H., Tateishi, Y., Hishima, T., Iwasaki, Y., Ishikawa, S., and Fukayama, M. (2012). ARID1A expression loss in gastric cancer: pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability. Virchows Arch 461, 367–377.
Alves, M.K., Ferrasi, A.C., Lima, V.P., Ferreira, M.V., de Moura Campos Pardini, M.I., and Rabenhorst, S.H. (2011). Inactivation of COX-2, HMLH1 and CDKN2A gene by promoter methylation in gastric cancer: relationship with histological subtype, tumor location and Helicobacter pylori genotype. Pathobiology 78, 266–276.
An, S.M., Ding, Q.P., and Li, L.S. (2013). Stem cell signaling as a target for novel drug discovery: recent progress in the WNT and Hedgehog pathways. Acta Pharmacol Sin 34, 777–783.
Anastas, J.N., and Moon, R.T. (2013). WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13, 11–26.
An, S.M., Ding, Q., Zhang, J., Xie, J.Y., and Li, L.S. (2014). Targeting stem cell signaling pathways for drug discovery: advances in the Notch and Wnt pathways. Sci China Life Sci 57, 575–580.
Appleton, K., Mackay, H.J., Judson, I., Plumb, J.A., McCormick, C., Strathdee, G., Lee, C., Barrett, S., Reade, S., Jadayel, D., Tang, A., Bellenger, K., Mackay, L., Setanoians, A., Schatzlein, A., Twelves, C., Kaye, S.B., and Brown, R. (2007). Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 25, 4603–4609.
Atencio, I.A., Grace, M., Bordens, R., Fritz, M., Horowitz, J.A., Hutchins, B., Indelicato, S., Jacobs, S., Kolz, K., Maneval, D., Musco, M.L., Shinoda, J., Venook, A., Wen, S., and Warren, R. (2006). Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial. Cancer Gene Ther 13, 169–181.
Attoub, S., Rivat, C., Rodrigues, S., Van Bocxlaer, S., Bedin, M., Bruyneel, E., Louvet, C., Kornprobst, M., Andre, T., Mareel, M., Mester, J., and Gespach, C. (2002). The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res 62, 4879–4883.
Baron, J.A., Cole, B.F., Sandler, R.S., Haile, R.W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R.W., Rothstein, R., Burke, C.A., Snover, D.C., Church, T.R., Allen, J.I., Beach, M., Beck, G.J., Bond, J.H., Byers, T., Greenberg, E.R., Mandel, J.S., Marcon, N., Mott, L.A., Pearson, L., Saibil, F., and van Stolk, R.U. (2003). A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348, 891–899.
Bellizzi, A., Mangia, A., Chiriatti, A., Petroni, S., Quaranta, M., Schittulli, F., Malfettone, A., Cardone, R.A., Paradiso, A., and Reshkin, S.J. (2008). RhoA protein expression in primary breast cancers and matched lymphocytes is associated with progression of the disease. Int J Mol Med 22, 25–31.
Belyi, V.A., Ak, P., Markert, E., Wang, H., Hu, W., Puzio-Kuter, A., and Levine, A.J. (2010). The origins and evolution of the p53 family of genes. Cold Spring Harb Perspect Biol 2, a001198.
Bitler, B.G., Aird, K.M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A.V., Schultz, D.C., Liu, Q., Shih Ie, M., Conejo-Garcia, J.R., Speicher, D.W., and Zhang, R. (2015). Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med 21, 231–238.
Bosse, T., ter Haar, N.T., Seeber, L.M., Diest, P.J., Hes, F.J., Vasen, H.F., Nout, R.A., Creutzberg, C.L., Morreau, H., and Smit, V.T. (2013). Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod Pathol 26, 1525–1535.
Bryant, H.E., Schultz, N., Thomas, H.D., Parker, K.M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N.J., and Helleday, T. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADPribose) polymerase. Nature 434, 913–917.
Buller, R.E., Runnebaum, I.B., Karlan, B.Y., Horowitz, J.A., Shahin, M., Buekers, T., Petrauskas, S., Kreienberg, R., Slamon, D., and Pegram, M. (2002). A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 9, 553–566.
Bykov, V.J., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K.G., and Selivanova, G. (2002). Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8, 282–288. Cancer Genome Atlas
Research, N. (2014). Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209.
Cao, R., and Zhang, Y. (2004). The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 14, 155–164.
Caputo, A., Caci, E., Ferrera, L., Pedemonte, N., Barsanti, C., Sondo, E., Pfeffer, U., Ravazzolo, R., Zegarra-Moran, O., and Galietta, L.J. (2008). TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science 322, 590–594.
Carrera, S., Buque, A., Azkona, E., Aresti, U., Calvo, B., Sancho, A., Arruti, M., Nuno, M., Rubio, I., de Lobera, A.R., Lopez, C., and Vivanco, G.L. (2014). Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies. Clin Transl Oncol 16, 339–350.
Celebiler Cavusoglu, A., Sevinc, A.I., Saydam, S., Canda, T., Baskan, Z., Kilic, Y., and Sakizli, M. (2010). Promoter methylation and expression changes of CDH1 and P16 genes in invasive breast cancer and adjacent normal breast tissue. Neoplasma 57, 465–472.
Cesar, A.C., Borim, A.A., Caetano, A., Cury, P.M., and Silva, A.E. (2004). Aneuploidies, deletion, and overexpression of TP53 gene in intestinal metaplasia of patients without gastric cancer. Cancer Genet Cytogenet 153, 127–132.
Chang, A.L., Solomon, J.A., Hainsworth, J.D., Goldberg, L., McKenna, E., Day, B.M., Chen, D.M., and Weiss, G.J. (2014). Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol 70, 60–69.
Chen, G.X., Zheng, L.H., Liu, S.Y., and He, X.H. (2011). rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy. World J Gastroenterol 17, 4289–4297.
Chen, T., Yang, K., Yu, J., Meng, W., Yuan, D., Bi, F., Liu, F., Liu, J., Dai, B., Chen, X., Wang, F., Zeng, F., Xu, H., Hu, J., and Mo, X. (2012). Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients. Cell Res 22, 248–258.
Chen, W., Zhang, X., Chu, C., Cheung, W.L., Ng, L., Lam, S., Chow, A., Lau, T., Chen, M., Li, Y., Nie, Y., Wong, B.C., and Pang, R. (2013). Identification of CD44+ cancer stem cells in human gastric cancer. Hepatogastroenterology 60, 949–954.
Cheng, A., Li, M., Kang, W., Cheng, V., Chou, J., Lau, S.S., Go, M.Y., Lee, C.C., Ling, T., Ng, E.K., Yu, J., Huang, T., To, K.F., Chan, M., Sung, J., and Chan, F. (2013). Helicobacter pylori causes epigenetic dysregulation of FOXD3 to promote gastric carcinogenesis. Gastroenterology 144, 122–133.e9.
Cheng, N., Hui, D.Y., Liu, Y., Zhang, N., Jiang, Y., Han, J., Li, H., Ding, Y., Du, H., Chen, J., and Shao, C. (2015). Is gastric lymphoepithelioma- like carcinoma a special subtype of EBV-associated gastric carcinoma? New insight based on clinicopathological features and EBV genome polymorphisms. Gastric Cancer 18, 246–255.
Cohen, D.J., Christos, P.J., Kindler, H.L., Catenacci, D.V.T., Bekaii-Saab, T.B., Tahiri, S., Janjigian, Y.Y., Gibson, M.K., Chan, E., Rajdev, L., Urba, S., Wade, J.L., Kozuch, P., Love, E., Vandris, K., Takebe, N., Hochster, H.S., Sparano, J.A., and Consortium, N.Y.C. (2013). Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led phase II randomized study. J Clin Oncol 31, 4011.
Cools, J. (2014). RHOA mutations in peripheral T cell lymphoma. Nat Genet 46, 320–321.
Egger, G., Liang, G., Aparicio, A., and Jones, P.A. (2004). Epigenetics in human disease and prospects for epigenetic therapy. Nature 429, 457–463.
Farmer, H., McCabe, N., Lord, C.J., Tutt, A.N., Johnson, D.A., Richardson, T.B., Santarosa, M., Dillon, K.J., Hickson, I., Knights, C., Martin, N.M., Jackson, S.P., Smith, G.C., and Ashworth, A. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921.
Fritz, G., Just, I., and Kaina, B. (1999). Rho GTPases are over-expressed in human tumors. Int J Cancer 81, 682–687.
Fuereder, T., Wanek, T., Pflegerl, P., Jaeger-Lansky, A., Hoeflmayer, D., Strommer, S., Kuntner, C., Wrba, F., Werzowa, J., Hejna, M., Muller, M., Langer, O., and Wacheck, V. (2011). Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake. Clin Cancer Res 17, 5322–5332.
Fukui, K., Tamura, S., Wada, A., Kamada, Y., Sawai, Y., Imanaka, K., Kudara, T., Shimomura, I., and Hayashi, N. (2006). Expression and prognostic role of RhoA GTPases in hepatocellular carcinoma. J Cancer Res Clin Oncol 132, 627–633.
Gamboa-Dominguez, A., Seidl, S., Reyes-Gutierrez, E., Hermannstadter, C., Quintanilla-Martinez, L., Busch, R., Hofler, H., Fend, F., and Luber, B. (2007). Prognostic significance of p21WAF1/CIP1, p27Kip1, p53 and E-cadherin expression in gastric cancer. J Clin Pathol 60, 756–761.
Gobbo Cesar, A.C., de Freitas Calmon, M., Cury, P.M., Caetano, A., Borim, A.A., and Silva, A.E. (2006). Genetic alterations in benign lesions: chronic gastritis and gastric ulcer. World J Gastroenterol 12, 625–629.
Gong, S.J., Jin, C.J., Rha, S.Y., and Chung, H.C. (2004). Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett 214, 215–224.
Gravalos, C., Gomez-Martin, C., Rivera, F., Ales, I., Queralt, B., Marquez, A., Jimenez, U., Alonso, V., Garcia-Carbonero, R., Sastre, J., Colomer, R., Cortes-Funes, H., and Jimeno, A. (2011). Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer. Clin Transl Oncol 13, 179–184.
Gravalos, C., and Jimeno, A. (2008). HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19, 1523–1529.
Grosch, S., Tegeder, I., Niederberger, E., Brautigam, L., and Geisslinger, G. (2001). COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 15, 2742–2744.
Group, G., Paoletti, X., Oba, K., Burzykowski, T., Michiels, S., Ohashi, Y., Pignon, J.P., Rougier, P., Sakamoto, J., Sargent, D., Sasako, M., Van Cutsem, E., and Buyse, M. (2010). Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 303, 1729–1737.
Guan, B., Wang, T.L., and Shih Ie, M. (2011). ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 71, 6718–6727.
Gur, S., Kadowitz, P.J., and Hellstrom, W.J. (2011). RhoA/Rho-kinase as a therapeutic target for the male urogenital tract. J Sex Med 8, 675–687.
He, D., Zhang, Y., Zhang, N., Zhou, L., Chen, J., Jiang, Y., and Shao, C. (2015). Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein-Barr virus-associated gastric carcinomas. Med Oncol 32, 92.
Iden, S., and Collard, J.G. (2008). Crosstalk between small GTPases and polarity proteins in cell polarization. Nat Rev Mol Cell Biol 9, 846–859.
Ikushima, H., and Miyazono, K. (2010). TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 10, 415–424.
Inada, R., Sekine, S., Taniguchi, H., Tsuda, H., Katai, H., Fujiwara, T., and Kushima, R. (2015). ARID1A expression in gastric adenocarcinoma: clinicopathological significance and correlation with DNA mismatch repair status. World J Gastroenterol 21, 2159–2168.
Iwamatsu, H., Nishikura, K., Watanabe, H., Ajioka, Y., Hashidate, H., Kashimura, H., and Asakura, H. (2001). Heterogeneity of p53 mutational status in the superficial spreading type of early gastric carcinoma. Gastric Cancer 4, 20–26.
Jablonowski, Z., Reszka, E., Gromadzinska, J., Wasowicz, W., and Sosnowski, M. (2011). Hypermethylation of p16 and DAPK promoter gene regions in patients with non-invasive urinary bladder cancer. Arch Med Sci 7, 512–516.
Jekimovs, C., Bolderson, E., Suraweera, A., Adams, M., O’Byrne, K.J., and Richard, D.J. (2014). Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising. Front Oncol 4, 86.
Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., and Forman, D. (2011). Global cancer statistics. CA Cancer J Clin 61, 69–90.
Justilien, V., and Fields, A.P. (2015). Molecular pathways: novel approaches for improved therapeutic targeting of Hedgehog signaling in cancer stem cells. Clin Cancer Res 21, 505–513.
Kahn, M. (2014). Can we safely target the WNT pathway? Nat Rev Drug Discov 13, 513–532.
Kakiuchi, M., Nishizawa, T., Ueda, H., Gotoh, K., Tanaka, A., Hayashi, A., Yamamoto, S., Tatsuno, K., Katoh, H., Watanabe, Y., Ichimura, T., Ushiku, T., Funahashi, S., Tateishi, K., Wada, I., Shimizu, N., Nomura, S., Koike, K., Seto, Y., Fukayama, M., Aburatani, H., and Ishikawa, S. (2014). Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet 46, 583–587.
Kaminskas, E., Farrell, A.T., Wang, Y.C., Sridhara, R., and Pazdur, R. (2005). FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 10, 176–182.
Kang, G.H. (2012). CpG island hypermethylation in gastric carcinoma and its premalignant lesions. Korean J Pathol 46, 1–9.
Katuri, V., Tang, Y., Li, C., Jogunoori, W., Deng, C.X., Rashid, A., Sidawy, A.N., Evans, S., Reddy, E.P., Mishra, B., and Mishra, L. (2006). Critical interactions between TGF-beta signaling/ELF, and E-cadherin/beta-catenin mediated tumor suppression. Oncogene 25, 1871–1886.
Kim, M.S., Je, E.M., Yoo, N.J., and Lee, S.H. (2012). Loss of ARID1A expression is uncommon in gastric, colorectal, and prostate cancers. APMIS 120, 1020–1022.
Klampfer, L. (2014). Vitamin D and colon cancer. World J Gastrointest Oncol 6, 430–437.
Kobayashi, M., Kawashima, A., Mai, M., and Ooi, A. (1996). Analysis of chromosome 17p13 (p53 locus) alterations in gastric carcinoma cells by dual-color fluorescence in situ hybridization. Am J Pathol 149, 1575–1584.
Koo, B.K., Spit, M., Jordens, I., Low, T.Y., Stange, D.E., van de Wetering, M., van Es, J.H., Mohammed, S., Heck, A.J., Maurice, M.M., and Clevers, H. (2012). Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors. Nature 488, 665–669.
Korkaya, H., Kim, G.I., Davis, A., Malik, F., Henry, N.L., Ithimakin, S., Quraishi, A.A., Tawakkol, N., D’Angelo, R., Paulson, A.K., Chung, S., Luther, T., Paholak, H.J., Liu, S., Hassan, K.A., Zen, Q., Clouthier, S.G., and Wicha, M.S. (2012). Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell 47, 570–584.
Lagasse, E. (2008). Cancer stem cells with genetic instability: the best vehicle with the best engine for cancer. Gene Ther 15, 136–142.
Larriba, M.J., Ordonez-Moran, P., Chicote, I., Martin-Fernandez, G., Puig, I., Munoz, A., and Palmer, H.G. (2011). Vitamin D receptor deficiency enhances Wnt/beta-catenin signaling and tumor burden in colon cancer. PLoS One 6, e23524.
Lauren, P. (1965). The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo- clinical classification. Acta Pathol Microbiol Scand 64, 31–49.
Lee, H.E., Han, N., Kim, M.A., Lee, H.S., Yang, H.K., Lee, B.L., and Kim, W.H. (2014). DNA damage response-related proteins in gastric cancer: ATM, Chk2 and p53 expression and their prognostic value. Pathobiology 81, 25–35.
Lehmann, S., Bykov, V.J., Ali, D., Andren, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., Paul, C., Wiman, K.G., and Andersson, P.O. (2012). Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 30, 3633–3639.
Leite, M., Corso, G., Sousa, S., Milanezi, F., Afonso, L.P., Henrique, R., Soares, J.M., Castedo, S., Carneiro, F., Roviello, F., Oliveira, C., and Seruca, R. (2011). MSI phenotype and MMR alterations in familial and sporadic gastric cancer. Int J Cancer 128, 1606–1613.
Levy, L., and Hill, C.S. (2005). Smad4 dependency defines two classes of transforming growth factor ta (TGF-ta) target genes and distinguishes TGF-ta-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol 25, 8108–8125.
Liang, H., Cheung, L.W., Li, J., Ju, Z., Yu, S., Stemke-Hale, K., Dogruluk, T., Lu, Y., Liu, X., Gu, C., Guo, W., Scherer, S.E., Carter, H., Westin, S.N., Dyer, M.D., Verhaak, R.G., Zhang, F., Karchin, R., Liu, C., Lu, K., Broaddus, R.R., Scott, K.L., Hennessy, B.T., and Mills, G.B. (2012). Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 22, 2120–2129.
Liu, F., Cao, Q., Lu, J., Luo, B., Lu, X., Luo, R., and Wang, X. (2015). TMEM16A overexpression contributes to tumor invasion and poor prognosis of human gastric cancer through TGF-beta signaling. Oncotarget 6, 11585–11599.
Liu, L., Lai, C.Q., Nie, L., Ordovas, J., Band, M., Moser, L., and Meydani, M. (2008). The modulation of endothelial cell gene expression by green tea polyphenol-EGCG. Mol Nutr Food Res 52, 1182–1192.
Liu, X., Wang, S., Xia, X., Chen, Y., Zhou, Y., Wu, X., Zhang, J., He, S., Tan, Y., Qiang, F., Roe, O.D., Li, G., and Zhou, J. (2012). Synergistic role between p53 and JWA: prognostic and predictive biomarkers in gastric cancer. PLoS One 7, e52348.
Lu, H., Wu, Y., Luo, W., Han, Y., Cai, Y., Xu, X., Liang, J., Liu, S., and Wang, M. (2009a). Correlation between aneuploidy of chromosome 17, over-expression of TP53 and TOPIIalpha, and the clinicopathological features and diagnosis of gastric adenocarcinoma. Zhonghua Zhong Liu Za Zhi 31, 754–758.
Lu, Q., Longo, F.M., Zhou, H., Massa, S.M., and Chen, Y.H. (2009b). Signaling through Rho GTPase pathway as viable drug target. Curr Med Chem 16, 1355–1365.
Mali, R.S., Ramdas, B., Ma, P., Shi, J., Munugalavadla, V., Sims, E., Wei, L., Vemula, S., Nabinger, S.C., Goodwin, C.B., Chan, R.J., Traina, F., Visconte, V., Tiu, R.V., Lewis, T.A., Stern, A.M., Wen, Q., Crispino, J.D., Boswell, H.S., and Kapur, R. (2011). Rho kinase regulates the survival and transformation of cells bearing oncogenic forms of KIT, FLT3, and BCR-ABL. Cancer Cell 20, 357–369.
Malissein, E., Meunier, E., Lajoie-Mazenc, I., Medale-Giamarchi, C., Dalenc, F., and Doisneau-Sixou, S.F. (2013). RhoA and RhoC differentially modulate estrogen receptor alpha recruitment, transcriptional activities, and expression in breast cancer cells (MCF-7). J Cancer Res Clin Oncol 139, 2079–2088.
Matsusaka, K., Kaneda, A., Nagae, G., Ushiku, T., Kikuchi, Y., Hino, R., Uozaki, H., Seto, Y., Takada, K., Aburatani, H., and Fukayama, M. (2011). Classification of Epstein-Barr virus-positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res 71, 7187–7197.
Merlo, A., Herman, J.G., Mao, L., Lee, D.J., Gabrielson, E., Burger, P.C., Baylin, S.B., and Sidransky, D. (1995). 5’ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1, 686–692.
Mishra, L., Shetty, K., Tang, Y., Stuart, A., and Byers, S.W. (2005). The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene 24, 5775–5789.
Molina, M.A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J., and Baselga, J. (2001). Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61, 4744–4749.
Molli, P.R., Pradhan, M.B., Advani, S.H., and Naik, N.R. (2012). RhoA: a therapeutic target for chronic myeloid leukemia. Mol Cancer 11, 16.
Na, H.K., and Woo, J.H. (2014). Helicobacter pylori induces hypermethylation of CpG islands through upregulation of DNA methyltransferase: possible involvement of reactive oxygen/nitrogen species. J Cancer Prev 19, 259–264.
Nagy, P., Friedlander, E., Tanner, M., Kapanen, A.I., Carraway, K.L., Isola, J., and Jovin, T.M. (2005). Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65, 473–482.
Nahta, R. (2012). Molecular mechanisms of trastuzumab-based treatment in HER2-overexpressing breast cancer. ISRN Oncol 2012, 428062.
Narumiya, S., Tanji, M., and Ishizaki, T. (2009). Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev 28, 65–76.
Nunes, K.P., Rigsby, C.S., and Webb, R.C. (2010). RhoA/Rho-kinase and vascular diseases: what is the link? Cell Mol Life Sci 67, 3823–3836.
Oh, S., Gwak, J., Park, S., and Yang, C. (2014). Green tea polyphenol EGCG suppresses Wnt/beta-catenin signaling by promoting GSK-3beta- and PP2A-independent beta-catenin phosphorylation/ degradation. Biofactors 40, 586–595.
Oki, E., Zhao, Y., Yoshida, R., Egashira, A., Ohgaki, K., Morita, M., Kakeji, Y., and Maehara, Y. (2009). The difference in p53 mutations between cancers of the upper and lower gastrointestinal tract. Digestion 79 Suppl 1, 33–39.
Olson, M.F. (2008). Applications for ROCK kinase inhibition. Curr Opin Cell Biol 20, 242–248.
Palomero, T., Couronne, L., Khiabanian, H., Kim, M.Y., Ambesi-Impiombato, A., Perez-Garcia, A., Carpenter, Z., Abate, F., Allegretta, M., Haydu, J.E., Jiang, X., Lossos, I.S., Nicolas, C., Balbin, M., Bastard, C., Bhagat, G., Piris, M.A., Campo, E., Bernard, O.A., Rabadan, R., and Ferrando, A.A. (2014). Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 46, 166–170.
Park, H.J., Kim, H.S., Kim, J.W., Park, S.Y., Kim, B.R., Ryu, H.Y., Lee, I.Y., Lee, Y.K., and Cho, M.Y. (2013). Is microsatellite instability (MSI) associated with multiplicity in early stage gastric neoplasias? Clin Res Hepatol Gastroenterol 37, 400–405.
Park, S.H., Kim, Y.S., Park, B.K., Hougaard, S., and Kim, S.J. (2001). Sequence-specific enhancer binding protein is responsible for the differential expression of ERT/ESX/ELF-3/ESE-1/jen gene in human gastric cancer cell lines: implication for the loss of TGF-beta type II receptor expression. Oncogene 20, 1235–1245.
Pohlmann, P., DiLeone, L.P., Cancella, A.I., Caldas, A.P., Dal Lago, L., Campos, O., Monego, E., Rivoire, W., and Schwartsmann, G. (2002). Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol 25, 496–501.
Prakash, S., Foster, B.J., Meyer, M., Wozniak, A., Heilbrun, L.K., Flaherty, L., Zalupski, M., Radulovic, L., Valdivieso, M., and LoRusso, P.M. (2001). Chronic oral administration of CI-994: a phase 1 study. Invest New Drugs 19, 1–11.
Qu, Y., Dang, S., and Hou, P. (2013). Gene methylation in gastric cancer. Clin Chim Acta 424, 53–65.
Ryu, K.D., Kim, G.H., Park, S.O., Lee, K.J., Moon, J.Y., Jeon, H.K., Baek, D.H., Lee, B.E., and Song, G.A. (2014). Treatment outcome for gastric mucosa-associated lymphoid tissue lymphoma according to Helicobacter pylori infection status: a single-center experience. Gut Liver 8, 408–414.
Sadok, A., McCarthy, A., Caldwell, J., Collins, I., Garrett, M.D., Yeo, M., Hooper, S., Sahai, E., Kuemper, S., Mardakheh, F.K., and Marshall, C.J. (2015). Rho kinase inhibitors block melanoma cell migration and inhibit metastasis. Cancer Res 75, 2272–2284.
Sahai, E., and Marshall, C.J. (2002). RHO-GTPases and cancer. Nat Rev Cancer 2, 133–142.
Sakata-Yanagimoto, M., Enami, T., Yoshida, K., Shiraishi, Y., Ishii, R., Miyake, Y., Muto, H., Tsuyama, N., Sato-Otsubo, A., Okuno, Y., Sakata, S., Kamada, Y., Nakamoto-Matsubara, R., Tran, N.B., Izutsu, K., Sato, Y., Ohta, Y., Furuta, J., Shimizu, S., Komeno, T., Sato, Y., Ito, T., Noguchi, M., Noguchi, E., Sanada, M., Chiba, K., Tanaka, H., Suzukawa, K., Nanmoku, T., Hasegawa, Y., Nureki, O., Miyano, S., Nakamura, N., Takeuchi, K., Ogawa, S., and Chiba, S. (2014). Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet 46, 171–175.
Samartzis, E.P., Gutsche, K., Dedes, K.J., Fink, D., Stucki, M., and Imesch, P. (2014). Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Oncotarget 5, 5295–5303.
Sandhiya, S., Melvin, G., Kumar, S.S., and Dkhar, S.A. (2013). The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother 4, 4–7.
Sandler, R.S., Halabi, S., Baron, J.A., Budinger, S., Paskett, E., Keresztes, R., Petrelli, N., Pipas, J.M., Karp, D.D., Loprinzi, C.L., Steinbach, G., and Schilsky, R. (2003). A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348, 883–890.
Senzer, N., and Nemunaitis, J. (2009). A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther 11, 54–61.
Shang, X., Marchioni, F., Evelyn, C.R., Sipes, N., Zhou, X., Seibel, W., Wortman, M., and Zheng, Y. (2013). Small-molecule inhibitors targeting G-protein-coupled Rho guanine nucleotide exchange factors. Proc Natl Acad Sci USA 110, 3155–3160.
Shang, X., Marchioni, F., Sipes, N., Evelyn, C.R., Jerabek-Willemsen, M., Duhr, S., Seibel, W., Wortman, M., and Zheng, Y. (2012). Rational design of small molecule inhibitors targeting RhoA subfamily Rho GTPases. Chem Biol 19, 699–710.
Siegel, R., Naishadham, D., and Jemal, A. (2013). Cancer statistics, 2013. CA Cancer J Clin 63, 11–30.
Smith, M.G., Hold, G.L., Tahara, E., and El-Omar, E.M. (2006). Cellular and molecular aspects of gastric cancer. World J Gastroenterol 12, 2979–2990.
So, J.Y., and Suh, N. (2015). Targeting cancer stem cells in solid tumors by vitamin D. J Steroid Biochem Mol Biol 148, 79–85.
Stojnev, S., Krstic, M., Ristic-Petrovic, A., Stefanovic, V., and Hattori, T. (2014). Gastric cancer stem cells: therapeutic targets. Gastric Cancer 17, 13–25.
Strong, M.J., Xu, G., Coco, J., Baribault, C., Vinay, D.S., Lacey, M.R., Strong, A.L., Lehman, T.A., Seddon, M.B., Lin, Z., Concha, M., Baddoo, M., Ferris, M., Swan, K.F., Sullivan, D.E., Burow, M.E., Taylor, C.M., and Flemington, E.K. (2013). Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy. PLoS Pathog 9, e1003341.
Sumiyoshi, Y., Kakeji, Y., Egashira, A., Mizokami, K., Orita, H., and Maehara, Y. (2006). Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res 12, 5112–5117.
Suzuki, K., and Matsubara, H. (2011). Recent advances in p53 research and cancer treatment. J Biomed Biotechnol 2011, 978312.
Tahara, E. (2004). Genetic pathways of two types of gastric cancer. IARC Sci Publ, 327–349.
Tang, Y., Katuri, V., Srinivasan, R., Fogt, F., Redman, R., Anand, G., Said, A., Fishbein, T., Zasloff, M., Reddy, E.P., Mishra, B., and Mishra, L. (2005). Transforming growth factor-beta suppresses nonmetastatic colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesis. Cancer Res 65, 4228–4237.
Ushiku, T., Ishikawa, S., Kakiuchi, M., Tanaka, A., Katoh, H., Aburatani, H., Lauwers, G.Y., and Fukayama, M. (2015). RHOA mutation in diffuse- type gastric cancer: a comparative clinicopathology analysis of 87 cases. Gastric Cancer 19, 403–411.
van Beusechem, V.W., van den Doel, P.B., Grill, J., Pinedo, H.M., and Gerritsen, W.R. (2002). Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res 62, 6165–6171.
Veganzones-de-Castro, S., Rafael-Fernandez, S., Vidaurreta-Lazaro, M., de-la-Orden, V., Mediero-Valeros, B., Fernandez, C., and Maestro-de las Casas, M.L. (2012). p16 gene methylation in colorectal cancer patients with long-term follow-up. Rev Esp Enferm Dig 104, 111–117.
Velho, S., Oliveira, C., Ferreira, A., Ferreira, A.C., Suriano, G., Schwartz, S., Duval, A., Carneiro, F., Machado, J.C., Hamelin, R., and Seruca, R. (2005). The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 41, 1649–1654.
Venkatanarayan, A., Raulji, P., Norton, W., Chakravarti, D., Coarfa, C., Su, X., Sandur, S.K., Ramirez, M.S., Lee, J., Kingsley, C.V., Sananikone, E.F., Rajapakshe, K., Naff, K., Parker-Thornburg, J., Bankson, J.A., Tsai, K.Y., Gunaratne, P.H., and Flores, E.R. (2015). IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo. Nature 517, 626–630.
Wang, D., Chen, Y., Pan, K., Wang, W., Chen, S., Chen, J., Zhao, J., Lv, L., Pan, Q., Li, Y., Wang, Q., Huang, L., Ke, M., He, J., and Xia, J. (2012). Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer. PLoS One 7, e40364.
Wang, K., Kan, J., Yuen, S.T., Shi, S.T., Chu, K.M., Law, S., Chan, T.L., Kan, Z., Chan, A.S., Tsui, W.Y., Lee, S.P., Ho, S.L., Chan, A.K., Cheng, G.H., Roberts, P.C., Rejto, P.A., Gibson, N.W., Pocalyko, D.J., Mao, M., Xu, J., and Leung, S.Y. (2011). Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 43, 1219–1223.
Wang, K., Yuen, S.T., Xu, J., Lee, S.P., Yan, H.H., Shi, S.T., Siu, H.C., Deng, S., Chu, K.M., Law, S., Chan, K.H., Chan, A.S., Tsui, W.Y., Ho, S.L., Chan, A.K., Man, J.L., Foglizzo, V., Ng, M.K., Chan, A.S., Ching, Y.P., Cheng, G.H., Xie, T., Fernandez, J., Li, V.S., Clevers, H., Rejto, P.A., Mao, M., and Leung, S.Y. (2014). Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 46, 573–582.
Wang, X., Su, C., Cao, H., Li, K., Chen, J., Jiang, L., Zhang, Q., Wu, X., Jia, X., Liu, Y., Wang, W., Liu, X., Wu, M., and Qian, Q. (2008). A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers. Mol Cancer Ther 7, 1598–1603.
Wei, K., Jiang, L., Wei, Y., Wang, Y., Qian, X., Dai, Q., and Guan, Q. (2015). The prognostic significance of p53 expression in gastric cancer: a meta-analysis. J Cancer Res Clin Oncol 141, 735–748.
Wilkes, G.M. (2012). Vismodegib, a hedgehog pathway inhibitor for adults with locally advanced or metastatic basal cell carcinoma. Oncology (Williston Park) 26, 31–33.
Wolf, J.K., Bodurka, D.C., Gano, J.B., Deavers, M., Ramondetta, L., Ramirez, P.T., Levenback, C., and Gershenson, D.M. (2004). A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinumand paclitaxel-resistant epithelial ovarian cancer. Gynecol Oncol 94, 442–448.
Xia, M., and Land, H. (2007). Tumor suppressor p53 restricts Ras stimulation of RhoA and cancer cell motility. Nat Struct Mol Biol 14, 215–223.
Xie, S., Zhang, Y., Li, Q., Wang, J., Li, J., Zhao, J., and Wang, C. (2012). COX-2-independent induction of apoptosis by celecoxib and polyamine naphthalimide conjugate mediated by polyamine depression in colorectal cancer cell lines. Int J Colorectal Dis 27, 861–868.
Yamamoto, S., Tsuda, H., Takano, M., Tamai, S., and Matsubara, O. (2012). PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Arch 460, 77–87.
Yamasaki, Y., Tazawa, H., Hashimoto, Y., Kojima, T., Kuroda, S., Yano, S., Yoshida, R., Uno, F., Mizuguchi, H., Ohtsuru, A., Urata, Y., Kagawa, S., and Fujiwara, T. (2012). A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression. Eur J Cancer 48, 2282–2291.
Yang, W., Raufi, A., and Klempner, S.J. (2014). Targeted therapy for gastric cancer: molecular pathways and ongoing investigations. Biochim Biophys Acta 1846, 232–237.
Yano, T., Doi, T., Ohtsu, A., Boku, N., Hashizume, K., Nakanishi, M., and Ochiai, A. (2006). Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 15, 65–71.
Yao, J., Qian, C., Shu, T., Zhang, X., Zhao, Z., and Liang, Y. (2013). Combination treatment of PD98059 and DAPT in gastric cancer through induction of apoptosis and downregulation of WNT/beta-catenin. Cancer Biol Ther 14, 833–839.
Yoo, C.B., and Jones, P.A. (2006). Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5, 37–50.
Yoo, H.Y., Sung, M.K., Lee, S.H., Kim, S., Lee, H., Park, S., Kim, S.C., Lee, B., Rho, K., Lee, J.E., Cho, K.H., Kim, W., Ju, H., Kim, J., Kim, S.J., Kim, W.S., Lee, S., and Ko, Y.H. (2014). A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet 46, 371–375.
Zang, Z.J., Cutcutache, I., Poon, S.L., Zhang, S.L., McPherson, J.R., Tao, J., Rajasegaran, V., Heng, H.L., Deng, N., Gan, A., Lim, K.H., Ong, C.K., Huang, D., Chin, S.Y., Tan, I.B., Ng, C.C., Yu, W., Wu, Y., Lee, M., Wu, J., Poh, D., Wan, W.K., Rha, S.Y., So, J., Salto-Tellez, M., Yeoh, K.G., Wong, W.K., Zhu, Y.J., Futreal, P.A., Pang, B., Ruan, Y., Hillmer, A.M., Bertrand, D., Nagarajan, N., Rozen, S., Teh, B.T., and Tan, P. (2012). Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 44, 570–574.
Zhang, A., Wang, Q., Han, Z., Hu, W., Xi, L., Gao, Q., Wang, S., Zhou, J., Xu, G., Meng, L., Chen, G., and Ma, D. (2013). Reduced expression of Snail decreases breast cancer cell motility by downregulating the expression and inhibiting the activity of RhoA GTPase. Oncol Lett 6, 339–346.
Zhang, B., Zhu, W., Yang, P., Liu, T., Jiang, M., He, Z.N., Zhang, S., Chen, W., and Chen, W. (2011a). Cigarette smoking and p16INK4alpha gene promoter hypermethylation in non-small cell lung carcinoma patients: a meta-analysis. PLoS One 6, e28882.
Zhang, C., Li, C., He, F., Cai, Y., and Yang, H. (2011b). Identification of CD44+CD24+ gastric cancer stem cells. J Cancer Res Clin Oncol 137, 1679–1686.
Zhao, C. (2014). Paracrine signaling in stem cell renewal and in neoplastic tumor growth. Sci China Life Sci 57, 571–574.
Zhou, J., Hayakawa, Y., Wang, T.C., and Bass, A.J. (2014). RhoA mutations identified in diffuse gastric cancer. Cancer Cell 26, 9–11.
Acknowledgements
This work was supported by the Science and Technology Commission of Shanghai Municipality (16ZR1410400, 14DZ2270100), and the State Scholarship Council (201506145040).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Guo, J., Yu, W., Su, H. et al. Genomic landscape of gastric cancer: molecular classification and potential targets. Sci. China Life Sci. 60, 126–137 (2017). https://doi.org/10.1007/s11427-016-0034-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-016-0034-1